LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
LifeMine Therapeutics, a US-based small molecule drug developer based on research at Harvard University, has secured $50m of series B funding co-led by Rick Klausner, a co-founder and the chairman.
Milky Way Investments co-led the round, while nternet and technology group Alphabet and pharmaceutical firms WuXi AppTec and Merck & Co took part through respective vehicles GV, WuXi Healthcare Ventures and MRL Ventures Fund.
Foresite Capital, Arch Ventures and Blue Pool Capital filled out the round.
LifeMine…
